Sickle Cell Disease Treatment

Global Market Trajectory & Analytics

MCP14727

EXECUTIVE ENGAGEMENTS

* Login for a full stack data experience

DATE

APR 2021

TABLES

111

182

EDITION

8

PRICE

USD $4950

HIGHLIGHTS

Amid the COVID-19 crisis, the global market for Sickle Cell Disease Treatment estimated at US$397.7 Million in the year 2020, is projected to reach a revised size of US$589.5 Million by 2027, growing at a CAGR of 5.8% over the analysis period 2020-2027. Hydroxyurea, one of the segments analyzed in the report, is projected to record a 5.4% CAGR and reach US$244.7 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Antibiotics segment is readjusted to a revised 6.8% CAGR for the next 7-year period.

The Sickle Cell Disease Treatment market in the U.S. is estimated at US$117.9 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$99.5 Million by the year 2027 trailing a CAGR of 4.9% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.9% and 5.1% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 3.1% CAGR.

In the global Pain-Relieving Medications segment, USA, Canada, Japan, China and Europe will drive the 5.7% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$66.8 Million in the year 2020 will reach a projected size of US$98.6 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$69.1 Million by the year 2027.

SELECT PLAYERS

Acceleron Pharma, Inc.; Alnylam Pharmaceuticals, Inc.; Arena Pharmaceuticals, Inc.; AstraZeneca PLC; Baxter International, Inc.; bluebird bio, Inc.; Bristol-Myers Squibb Company; Eli Lilly and Company; Emmaus Life Sciences, Inc.; Global Blood Therapeutics, Inc.; Novartis AG; Pfizer, Inc.; Sangamo Therapeutics, Inc.

SEGMENTS

» Disease Type (Sickle Cell Anemia, Sickle Hemoglobin C Disease, Sickle Beta Thalassemia, Other Disease Types) » Drug Type (Hydroxyurea, Antibiotics, Pain-Relieving Medications, Other Drug Types)

GEOGRAPHIES

» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

Influencer Market Insights

World Market Trajectories

Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

World Current & Future Analysis for Sickle Cell Disease Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR

World Historic Review for Sickle Cell Disease Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

World 15-Year Perspective for Sickle Cell Disease Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027

World Current & Future Analysis for Hydroxyurea by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR

World Historic Review for Hydroxyurea by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

World 15-Year Perspective for Hydroxyurea by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

World Current & Future Analysis for Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR

World Historic Review for Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

World 15-Year Perspective for Antibiotics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

World Current & Future Analysis for Pain-Relieving Medications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR

World Historic Review for Pain-Relieving Medications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

World 15-Year Perspective for Pain-Relieving Medications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

World Current & Future Analysis for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR

World Historic Review for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

World 15-Year Perspective for Other Drug Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

World Current & Future Analysis for Sickle Cell Anemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR

World Historic Review for Sickle Cell Anemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

World 15-Year Perspective for Sickle Cell Anemia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

World Current & Future Analysis for Sickle Hemoglobin C Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR

World Historic Review for Sickle Hemoglobin C Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

World 15-Year Perspective for Sickle Hemoglobin C Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

World Current & Future Analysis for Sickle Beta Thalassemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR

World Historic Review for Sickle Beta Thalassemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

World 15-Year Perspective for Sickle Beta Thalassemia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

World Current & Future Analysis for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR

World Historic Review for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

World 15-Year Perspective for Other Disease Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

UNITED STATES

USA Current & Future Analysis for Sickle Cell Disease Treatment by Drug Type - Hydroxyurea, Antibiotics, Pain-Relieving Medications and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

USA Historic Review for Sickle Cell Disease Treatment by Drug Type - Hydroxyurea, Antibiotics, Pain-Relieving Medications and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

USA 15-Year Perspective for Sickle Cell Disease Treatment by Drug Type - Percentage Breakdown of Value Sales for Hydroxyurea, Antibiotics, Pain-Relieving Medications and Other Drug Types for the Years 2012, 2020 & 2027

USA Current & Future Analysis for Sickle Cell Disease Treatment by Disease Type - Sickle Cell Anemia, Sickle Hemoglobin C Disease, Sickle Beta Thalassemia and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

USA Historic Review for Sickle Cell Disease Treatment by Disease Type - Sickle Cell Anemia, Sickle Hemoglobin C Disease, Sickle Beta Thalassemia and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

USA 15-Year Perspective for Sickle Cell Disease Treatment by Disease Type - Percentage Breakdown of Value Sales for Sickle Cell Anemia, Sickle Hemoglobin C Disease, Sickle Beta Thalassemia and Other Disease Types for the Years 2012, 2020 & 2027

CANADA

Canada Current & Future Analysis for Sickle Cell Disease Treatment by Drug Type - Hydroxyurea, Antibiotics, Pain-Relieving Medications and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

Canada Historic Review for Sickle Cell Disease Treatment by Drug Type - Hydroxyurea, Antibiotics, Pain-Relieving Medications and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Canada 15-Year Perspective for Sickle Cell Disease Treatment by Drug Type - Percentage Breakdown of Value Sales for Hydroxyurea, Antibiotics, Pain-Relieving Medications and Other Drug Types for the Years 2012, 2020 & 2027

Canada Current & Future Analysis for Sickle Cell Disease Treatment by Disease Type - Sickle Cell Anemia, Sickle Hemoglobin C Disease, Sickle Beta Thalassemia and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

Canada Historic Review for Sickle Cell Disease Treatment by Disease Type - Sickle Cell Anemia, Sickle Hemoglobin C Disease, Sickle Beta Thalassemia and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Canada 15-Year Perspective for Sickle Cell Disease Treatment by Disease Type - Percentage Breakdown of Value Sales for Sickle Cell Anemia, Sickle Hemoglobin C Disease, Sickle Beta Thalassemia and Other Disease Types for the Years 2012, 2020 & 2027

JAPAN

Japan Current & Future Analysis for Sickle Cell Disease Treatment by Drug Type - Hydroxyurea, Antibiotics, Pain-Relieving Medications and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

Japan Historic Review for Sickle Cell Disease Treatment by Drug Type - Hydroxyurea, Antibiotics, Pain-Relieving Medications and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Japan 15-Year Perspective for Sickle Cell Disease Treatment by Drug Type - Percentage Breakdown of Value Sales for Hydroxyurea, Antibiotics, Pain-Relieving Medications and Other Drug Types for the Years 2012, 2020 & 2027

Japan Current & Future Analysis for Sickle Cell Disease Treatment by Disease Type - Sickle Cell Anemia, Sickle Hemoglobin C Disease, Sickle Beta Thalassemia and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

Japan Historic Review for Sickle Cell Disease Treatment by Disease Type - Sickle Cell Anemia, Sickle Hemoglobin C Disease, Sickle Beta Thalassemia and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Japan 15-Year Perspective for Sickle Cell Disease Treatment by Disease Type - Percentage Breakdown of Value Sales for Sickle Cell Anemia, Sickle Hemoglobin C Disease, Sickle Beta Thalassemia and Other Disease Types for the Years 2012, 2020 & 2027

CHINA

China Current & Future Analysis for Sickle Cell Disease Treatment by Drug Type - Hydroxyurea, Antibiotics, Pain-Relieving Medications and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

China Historic Review for Sickle Cell Disease Treatment by Drug Type - Hydroxyurea, Antibiotics, Pain-Relieving Medications and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

China 15-Year Perspective for Sickle Cell Disease Treatment by Drug Type - Percentage Breakdown of Value Sales for Hydroxyurea, Antibiotics, Pain-Relieving Medications and Other Drug Types for the Years 2012, 2020 & 2027

China Current & Future Analysis for Sickle Cell Disease Treatment by Disease Type - Sickle Cell Anemia, Sickle Hemoglobin C Disease, Sickle Beta Thalassemia and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

China Historic Review for Sickle Cell Disease Treatment by Disease Type - Sickle Cell Anemia, Sickle Hemoglobin C Disease, Sickle Beta Thalassemia and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

China 15-Year Perspective for Sickle Cell Disease Treatment by Disease Type - Percentage Breakdown of Value Sales for Sickle Cell Anemia, Sickle Hemoglobin C Disease, Sickle Beta Thalassemia and Other Disease Types for the Years 2012, 2020 & 2027

EUROPE

Europe Current & Future Analysis for Sickle Cell Disease Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR

Europe Historic Review for Sickle Cell Disease Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Europe 15-Year Perspective for Sickle Cell Disease Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027

Europe Current & Future Analysis for Sickle Cell Disease Treatment by Drug Type - Hydroxyurea, Antibiotics, Pain-Relieving Medications and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

Europe Historic Review for Sickle Cell Disease Treatment by Drug Type - Hydroxyurea, Antibiotics, Pain-Relieving Medications and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Europe 15-Year Perspective for Sickle Cell Disease Treatment by Drug Type - Percentage Breakdown of Value Sales for Hydroxyurea, Antibiotics, Pain-Relieving Medications and Other Drug Types for the Years 2012, 2020 & 2027

Europe Current & Future Analysis for Sickle Cell Disease Treatment by Disease Type - Sickle Cell Anemia, Sickle Hemoglobin C Disease, Sickle Beta Thalassemia and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

Europe Historic Review for Sickle Cell Disease Treatment by Disease Type - Sickle Cell Anemia, Sickle Hemoglobin C Disease, Sickle Beta Thalassemia and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Europe 15-Year Perspective for Sickle Cell Disease Treatment by Disease Type - Percentage Breakdown of Value Sales for Sickle Cell Anemia, Sickle Hemoglobin C Disease, Sickle Beta Thalassemia and Other Disease Types for the Years 2012, 2020 & 2027

FRANCE

France Current & Future Analysis for Sickle Cell Disease Treatment by Drug Type - Hydroxyurea, Antibiotics, Pain-Relieving Medications and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

France Historic Review for Sickle Cell Disease Treatment by Drug Type - Hydroxyurea, Antibiotics, Pain-Relieving Medications and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

France 15-Year Perspective for Sickle Cell Disease Treatment by Drug Type - Percentage Breakdown of Value Sales for Hydroxyurea, Antibiotics, Pain-Relieving Medications and Other Drug Types for the Years 2012, 2020 & 2027

France Current & Future Analysis for Sickle Cell Disease Treatment by Disease Type - Sickle Cell Anemia, Sickle Hemoglobin C Disease, Sickle Beta Thalassemia and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

France Historic Review for Sickle Cell Disease Treatment by Disease Type - Sickle Cell Anemia, Sickle Hemoglobin C Disease, Sickle Beta Thalassemia and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

France 15-Year Perspective for Sickle Cell Disease Treatment by Disease Type - Percentage Breakdown of Value Sales for Sickle Cell Anemia, Sickle Hemoglobin C Disease, Sickle Beta Thalassemia and Other Disease Types for the Years 2012, 2020 & 2027

GERMANY

Germany Current & Future Analysis for Sickle Cell Disease Treatment by Drug Type - Hydroxyurea, Antibiotics, Pain-Relieving Medications and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

Germany Historic Review for Sickle Cell Disease Treatment by Drug Type - Hydroxyurea, Antibiotics, Pain-Relieving Medications and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Germany 15-Year Perspective for Sickle Cell Disease Treatment by Drug Type - Percentage Breakdown of Value Sales for Hydroxyurea, Antibiotics, Pain-Relieving Medications and Other Drug Types for the Years 2012, 2020 & 2027

Germany Current & Future Analysis for Sickle Cell Disease Treatment by Disease Type - Sickle Cell Anemia, Sickle Hemoglobin C Disease, Sickle Beta Thalassemia and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

Germany Historic Review for Sickle Cell Disease Treatment by Disease Type - Sickle Cell Anemia, Sickle Hemoglobin C Disease, Sickle Beta Thalassemia and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Germany 15-Year Perspective for Sickle Cell Disease Treatment by Disease Type - Percentage Breakdown of Value Sales for Sickle Cell Anemia, Sickle Hemoglobin C Disease, Sickle Beta Thalassemia and Other Disease Types for the Years 2012, 2020 & 2027

ITALY

Italy Current & Future Analysis for Sickle Cell Disease Treatment by Drug Type - Hydroxyurea, Antibiotics, Pain-Relieving Medications and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

Italy Historic Review for Sickle Cell Disease Treatment by Drug Type - Hydroxyurea, Antibiotics, Pain-Relieving Medications and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Italy 15-Year Perspective for Sickle Cell Disease Treatment by Drug Type - Percentage Breakdown of Value Sales for Hydroxyurea, Antibiotics, Pain-Relieving Medications and Other Drug Types for the Years 2012, 2020 & 2027

Italy Current & Future Analysis for Sickle Cell Disease Treatment by Disease Type - Sickle Cell Anemia, Sickle Hemoglobin C Disease, Sickle Beta Thalassemia and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

Italy Historic Review for Sickle Cell Disease Treatment by Disease Type - Sickle Cell Anemia, Sickle Hemoglobin C Disease, Sickle Beta Thalassemia and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Italy 15-Year Perspective for Sickle Cell Disease Treatment by Disease Type - Percentage Breakdown of Value Sales for Sickle Cell Anemia, Sickle Hemoglobin C Disease, Sickle Beta Thalassemia and Other Disease Types for the Years 2012, 2020 & 2027

UNITED KINGDOM

UK Current & Future Analysis for Sickle Cell Disease Treatment by Drug Type - Hydroxyurea, Antibiotics, Pain-Relieving Medications and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

UK Historic Review for Sickle Cell Disease Treatment by Drug Type - Hydroxyurea, Antibiotics, Pain-Relieving Medications and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

UK 15-Year Perspective for Sickle Cell Disease Treatment by Drug Type - Percentage Breakdown of Value Sales for Hydroxyurea, Antibiotics, Pain-Relieving Medications and Other Drug Types for the Years 2012, 2020 & 2027

UK Current & Future Analysis for Sickle Cell Disease Treatment by Disease Type - Sickle Cell Anemia, Sickle Hemoglobin C Disease, Sickle Beta Thalassemia and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

UK Historic Review for Sickle Cell Disease Treatment by Disease Type - Sickle Cell Anemia, Sickle Hemoglobin C Disease, Sickle Beta Thalassemia and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

UK 15-Year Perspective for Sickle Cell Disease Treatment by Disease Type - Percentage Breakdown of Value Sales for Sickle Cell Anemia, Sickle Hemoglobin C Disease, Sickle Beta Thalassemia and Other Disease Types for the Years 2012, 2020 & 2027

REST OF EUROPE

Rest of Europe Current & Future Analysis for Sickle Cell Disease Treatment by Drug Type - Hydroxyurea, Antibiotics, Pain-Relieving Medications and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

Rest of Europe Historic Review for Sickle Cell Disease Treatment by Drug Type - Hydroxyurea, Antibiotics, Pain-Relieving Medications and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Rest of Europe 15-Year Perspective for Sickle Cell Disease Treatment by Drug Type - Percentage Breakdown of Value Sales for Hydroxyurea, Antibiotics, Pain-Relieving Medications and Other Drug Types for the Years 2012, 2020 & 2027

Rest of Europe Current & Future Analysis for Sickle Cell Disease Treatment by Disease Type - Sickle Cell Anemia, Sickle Hemoglobin C Disease, Sickle Beta Thalassemia and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

Rest of Europe Historic Review for Sickle Cell Disease Treatment by Disease Type - Sickle Cell Anemia, Sickle Hemoglobin C Disease, Sickle Beta Thalassemia and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Rest of Europe 15-Year Perspective for Sickle Cell Disease Treatment by Disease Type - Percentage Breakdown of Value Sales for Sickle Cell Anemia, Sickle Hemoglobin C Disease, Sickle Beta Thalassemia and Other Disease Types for the Years 2012, 2020 & 2027

ASIA-PACIFIC

Asia-Pacific Current & Future Analysis for Sickle Cell Disease Treatment by Drug Type - Hydroxyurea, Antibiotics, Pain-Relieving Medications and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

Asia-Pacific Historic Review for Sickle Cell Disease Treatment by Drug Type - Hydroxyurea, Antibiotics, Pain-Relieving Medications and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Asia-Pacific 15-Year Perspective for Sickle Cell Disease Treatment by Drug Type - Percentage Breakdown of Value Sales for Hydroxyurea, Antibiotics, Pain-Relieving Medications and Other Drug Types for the Years 2012, 2020 & 2027

Asia-Pacific Current & Future Analysis for Sickle Cell Disease Treatment by Disease Type - Sickle Cell Anemia, Sickle Hemoglobin C Disease, Sickle Beta Thalassemia and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

Asia-Pacific Historic Review for Sickle Cell Disease Treatment by Disease Type - Sickle Cell Anemia, Sickle Hemoglobin C Disease, Sickle Beta Thalassemia and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Asia-Pacific 15-Year Perspective for Sickle Cell Disease Treatment by Disease Type - Percentage Breakdown of Value Sales for Sickle Cell Anemia, Sickle Hemoglobin C Disease, Sickle Beta Thalassemia and Other Disease Types for the Years 2012, 2020 & 2027

REST OF WORLD

Rest of World Current & Future Analysis for Sickle Cell Disease Treatment by Drug Type - Hydroxyurea, Antibiotics, Pain-Relieving Medications and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

Rest of World Historic Review for Sickle Cell Disease Treatment by Drug Type - Hydroxyurea, Antibiotics, Pain-Relieving Medications and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Rest of World 15-Year Perspective for Sickle Cell Disease Treatment by Drug Type - Percentage Breakdown of Value Sales for Hydroxyurea, Antibiotics, Pain-Relieving Medications and Other Drug Types for the Years 2012, 2020 & 2027

Rest of World Current & Future Analysis for Sickle Cell Disease Treatment by Disease Type - Sickle Cell Anemia, Sickle Hemoglobin C Disease, Sickle Beta Thalassemia and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

Rest of World Historic Review for Sickle Cell Disease Treatment by Disease Type - Sickle Cell Anemia, Sickle Hemoglobin C Disease, Sickle Beta Thalassemia and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Rest of World 15-Year Perspective for Sickle Cell Disease Treatment by Disease Type - Percentage Breakdown of Value Sales for Sickle Cell Anemia, Sickle Hemoglobin C Disease, Sickle Beta Thalassemia and Other Disease Types for the Years 2012, 2020 & 2027

IV. COMPETITION

Total Companies Profiled: 41

PREVIEW REPORT

YOUR PRIVACY MATTERS!

Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.

What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com

DIFFERENTIATORS

Integrity Trust Transparency

Our research offerings primarily draw upon unique perspectives of participating executives and their experiences in operating and strategy roles. These geo-focused insights enrich our projects .

What we are NOT - Our reports are not editorial exercises of remote analysts’ secondary source fed content that predominantly flood today’s off-the-shelf market report business. (A review of 262 publishers).

WHAT SETS US APART

FULL STACK DATA ACCESS

Primary Research Cluster Data
Influencer Engagement Stats
Evidence of Primary Research
List of Companies Engaged
Hundreds of Pages of Research
Peer Collaborative Interactions
Enterprise Data Exchanges
MarketGlassTM Platform Insider
Geographic Pricing Dynamics
Competitive Shares by Country
Brand Curation & Insights
Domain Expert Pool

Program Transparency: Clients have access to engagement stats of companies and executives. Clients may commission third-party audits of our influencer engagements at their expense.

Primary Research: We have a very successful incentive driven primary research program presenting a rich experience to participating executives. Featured company executives can sign up for a complimentary.

Collaborative Intelligence: Our platform presents a unique features for executives to collaborate with peers across geographies and participate on various product or regional perspectives for a collective unified insider project experience.

Global Brand Intelligence: We present competitive brand intelligence at the company level for players worldwide. Executives from brand owner companies participate to curate each brand for relevance and market presence.

Bespoke Updates: Our peer-to-peer online interactive platform enables client companies to build upon our project data stacks to build bespoke editions for internal sharing and use. Client company can build one complimentary update per year and unlimited updates for additional fee. Bespoke updates are fulfilled within a two-day turnaround.

Enterprise EcoConnect: Discretely bounce off queries to participant pool of executives. We can reach out to our participant pool based on specifics of geographic or domain acumen.

Renowned Support: We pride in our commitment to provide support to our clients. We go beyond the scope of the study to get you timely answers.

Complimentary Updates: Unlike the industry’s published PDF’s that are frozen in time from date of release, our research programs are ongoing and dynamic. Our reports are updated whenever there’s a major event impacting the marketplace. Your license offers seamless updates for one year.

No Fluff: We offer our clients the best CX with clean easy to read content. No verbose fluff. We offer clients full access to the entire stack of hundreds of pages of secondary research feeds used in our project via our online MarketGlass portal.

REPORT PREVIEW